Oncology

Top Medical News
Switching from cetuximab to bevacizumab associated with reduced derm toxicity in mCRC
Natalia Reoutova, 2 days ago

Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab leads to acceptable survival outcomes and a reduction in severe dermatological toxicities in patients with RAS wild-type (RASwt) metastatic colorectal cancer (mCRC), according to the results of a single-arm phase II HYBRID trial.

Paediatric-onset immune-mediated inflammatory diseases raise mortality risk
3 days ago
People with paediatric-onset immune-mediated inflammatory diseases (pIMID) have a roughly fourfold increased risk of death in adulthood, as suggested in a study.
Maintenance olaparib + bevacizumab support long-term remission in HRD-positive ovarian cancer
Natalia Reoutova, 3 days ago

Post hoc analysis of the phase III PAOLA-1/ENGOT-ov25 trial reports respective 5-year progression-free survival (PFS) rates of 72 percent vs 28 percent and 5-year overall survival (OS) rates of 88 percent vs 61 percent for maintenance olaparib plus bevacizumab vs bevacizumab alone in lower-risk homologous recombination deficiency (HRD)–positive patients with newly diagnosed advanced ovarian cancer.

Do GLP1 receptor agonists increase thyroid cancer risk?
Stephen Padilla, 4 days ago
Use of glucagon-like peptide 1 (GLP1) receptor agonists does not contribute to an elevated risk of thyroid cancer, as shown in a Scandinavian cohort study with a mean follow-up of nearly 4 years.
Managing diabetes in primary care
5 days ago
For individuals with diabetes mellitus (DM), optimal glycaemic control may protect against the risk of developing colonic adenoma and colorectal cancer (CRC), as reported in a population-based cohort study.
Neoadjuvant nivolumab plus chemo: New SoC in resectable NSCLC
Jairia Dela Cruz, 5 days ago
Treatment with nivolumab plus chemotherapy before surgery followed by nivolumab after surgery yields superior outcomes for patients with resectable nonsmall cell lung cancer (NSCLC) as compared with placebo plus chemotherapy, regardless of the number of completed neoadjuvant cycles, according to an exploratory analysis of the CHECKMATE 77T trial.
Injectable atezolizumab favoured over intravenous infusion
Jairia Dela Cruz, 6 days ago
Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.
Special Reports
SARS-CoV-2 Variants: Everything you need to know
01 Feb 2023
The COVID-19 pandemic continues to evolve with the emergence of new SARS-CoV-2 variants. The variants of concern have the potential to impact the transmissibility, virulence, and clinical presentation of the disease, affecting the epidemiology, public health measures, and diagnostic and therapeutic options. Mutations in the spike protein of the virus have increased its ability to infect humans and evade neutralization by natural or immunisation-induced antibodies. The highly mutated Omicron variant of SARS-CoV-2 has multiple sublineages with varying transmissibility and immune evasion potential. Pre-exposure prophylaxis plays a crucial role in protecting the immunocompromised populations against severe disease; however, the rapidly changing landscape of the variants poses a major challenge to the current and future effectiveness of pre-exposure prophylactic monoclonal antibodies.
New treatment option now available for patients with HR+/HER2- aBC/MBC, PIK3CA mutations
31 Mar 2021
At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.
Management of MDROs in the ICU and the role of newer antimicrobial agents
Prof. David Paterson, 30 Mar 2021
Intensive care unit (ICU) patients are at risk of developing serious infections with multidrug-resistant organisms (MDROs), which require appropriate and adequate antibiotic coverage. Early empirical coverage is pivotal in saving patients’ lives. At a recent webinar co-organized by the Society of Infectious Disease (Singapore) and Pfizer, renowned Professor David Paterson, Professor of Medicine and Director, The University of Queensland Centre for Clinical Research, and Consultant Infectious Diseases Physician, Royal Brisbane and Women’s Hospital, Brisbane, Australia, discussed the role of newer antimicrobial agents, including ceftazidime-avibactam (Zavicefta) in the management of MDROs in the ICU. Dr Wong Sin Yew, Infectious Disease Physician at Gleneagles Medical Centre and Mount Elizabeth Novena Specialist Centre, Singapore, chaired the event.
The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib
Dr. Wong Seng Weng, Dr. Lee Guek Eng, 19 Mar 2021
In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.
Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas. 
ALL treatment: Current settings, future goals
Roshini Claire Anthony, 08 Jan 2021

Significant advancements in the treatment of acute lymphocytic leukaemia (ALL) in children have improved their outcomes. However, ALL treatment and eradication remain a major challenge in adults. In a recent webinar, two specialists from the US discussed current ALL treatment strategies and goals of future regimens.

Carfilzomib-based triplet regimen a potential upfront treatment for high-risk MM
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Conference Reports
Neoadjuvant nivolumab plus chemo: New SoC in resectable NSCLC
Jairia Dela Cruz, 19 Apr 2024
Treatment with nivolumab plus chemotherapy before surgery followed by nivolumab after surgery yields superior outcomes for patients with resectable nonsmall cell lung cancer (NSCLC) as compared with placebo plus chemotherapy, regardless of the number of completed neoadjuvant cycles, according to an exploratory analysis of the CHECKMATE 77T trial.
Injectable atezolizumab favoured over intravenous infusion
Jairia Dela Cruz, 18 Apr 2024
Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.
Amivantamab plus chemo tied to better outcomes in NSCLC
Stephen Padilla, 17 Apr 2024
Treatment with amivantamab (ami) in combination with chemotherapy (chemo) results in substantially longer time to treatment discontinuation (TTD), time to subsequent therapy (TTST), and progression-free survival (PFS) after first subsequent therapy (PFS2) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NSCLC) following progression on osimertinib, as shown in a postprogression analysis.
Apixaban cheaper, on par with enoxaparin as VTE prophylaxis in gynaecologic cancer patients
Stephen Padilla, 12 Apr 2024
Patients with gynaecologic cancer who used apixaban for postoperative venous thromboembolism (VTE) prophylaxis achieve similar 90-day and lower 30-day rates of VTE when compared with those who used enoxaparin, reports a study presented at SGO 2024.
Maintenance fuzuloparib prolongs survival in ovarian cancer
Stephen Padilla, 12 Apr 2024
Maintenance therapy with fuzuloparib results in significant improvements in progression-free survival (PFS) in patients newly diagnosed with advanced ovarian cancer, who showed response to first-line platinum-based chemotherapy (PBC), reports a study (FZOCUS-1) presented at SGO 2024.
Niraparib maintenance yields favourable OS trend in patients with ovarian cancer
Elaine Soliven, 12 Apr 2024

Maintenance treatment with niraparib, a potent, highly selective PARP* inhibitor, provides a favourable overall survival (OS) trend compared with placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), regardless of germline BRCA (gBRCA) mutation status, according to the final analysis of the NORA trial presented at SGO 2024.

Survival outcomes similar between minimally invasive interval debulking surgery and laparotomy
Jairia Dela Cruz, 05 Apr 2024
A minimally invasive approach to interval debulking surgery appears to be just as effective as the use of an open technique for epithelial ovarian cancer, with no significant difference in overall survival (OS) when complete tumour resection is achieved, according to a study.